Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Retatrutide vs Semaglutide: Triple Agonist vs GLP-1, Compared

Retatrutide is an investigational triple agonist (GIP + GLP-1 + glucagon); semaglutide is an FDA-approved GLP-1 single agonist. In their own trials, retatrutide reached ~24.2% mean weight reduction at 48 weeks (Phase 2) versus semaglutide’s ~14.9% at 68 weeks (STEP-1). They have never been tested head-to-head , and only semaglutide is approved.

No head-to-head trial exists. The figures below come from separate studies with different populations, durations, doses and endpoints. Cross-trial percentages are indicative only — they are not evidence that one compound outperforms another. All data is presented for research context; nothing here is medical or dosing guidance.

At a glance

Retatrutide Semaglutide Receptor targets GIP + GLP-1 + glucagon (triple) GLP-1 only (single) Developer Eli Lilly (LY3437943) Novo Nordisk (Ozempic / Wegovy) Trial stage Phase 3 (TRIUMPH) ongoing FDA-approved Headline weight data ~24.2% at 48 wk (Phase 2, 12 mg) ~14.9% at 68 wk (STEP-1) Dosing cadence Once-weekly (trials) Once-weekly (also oral form) Approval None yet (investigational) Type 2 diabetes & weight management

One receptor vs three

Semaglutide is the reference GLP-1 mono-agonist — it acts on a single incretin receptor and set the modern benchmark for the class. Retatrutide layers GIP and glucagon agonism on top of GLP-1.

Semaglutide — single

GLP-1 receptor only. The most studied, most prescribed molecule in the class, with the deepest long-term dataset.

Retatrutide — triple

GIP + GLP-1 + glucagon. Broader receptor engagement, larger early weight numbers, but far less long-term evidence.

What the trials showed

Retatrutide (Phase 2, NEJM 2023): up to 24.2% mean weight reduction at 48 weeks (12 mg), still rising at trial end. Phase 3 TRIUMPH-1 has reported reductions up to ~28% at 80 weeks.

Semaglutide (STEP-1, Phase 3): mean weight reduction of ~14.9% at 68 weeks at 2.4 mg — the result that reset expectations for GLP-1 therapy.

The cross-trial gap looks large, but semaglutide’s numbers come from a completed, approved programme, while retatrutide’s come from earlier-phase research still being confirmed. Depth of evidence and regulatory status weigh against a raw percentage.

Regulatory status

Semaglutide is FDA-approved (Ozempic for type 2 diabetes, Wegovy for weight management, plus an oral form). Retatrutide is investigational with no approval and is a research compound only.

Side-effect profiles

Both are dominated by dose-dependent gastrointestinal effects that ease with gradual titration in trials. Semaglutide’s safety profile is the most mature in the class thanks to years of post-approval use. Retatrutide trials additionally flagged heart-rate increases and glucagon-arm metabolic parameters that Phase 3 is designed to characterise.

Research takeaway

Retatrutide = GLP-1R / GIPR / GCGR agonism characterised in research; investigational, no marketing authorisation.

Semaglutide = GLP-1 mono-agonist, approved, deepest evidence base.

No head-to-head data — the percentage gap is cross-trial, not a verdict.

Both are supplied by New-U strictly as research compounds.

Retatrutide & semaglutide, lab-direct

New-U supplies both as >99% HPLC-verified research compounds with the per-batch Certificate of Analysis published online. Research use only - all claims made on this site are for testing and research use only.

Frequently asked questions

Is retatrutide stronger than semaglutide?

In their separate trials retatrutide reached ~24.2% mean weight reduction at 48 weeks versus semaglutide’s ~14.9% at 68 weeks, but no head-to-head trial exists, so this is a cross-trial comparison only. Semaglutide is approved with mature data; retatrutide is investigational. Research context only.

What is the difference between retatrutide and semaglutide?

Semaglutide is a single GLP-1 receptor agonist; retatrutide is a triple agonist adding GIP and glucagon receptors. Semaglutide is FDA-approved; retatrutide is still in Phase 3 trials.

Is retatrutide approved like Ozempic or Wegovy?

No. Semaglutide (Ozempic, Wegovy) is FDA-approved. Retatrutide has no approval and is an investigational research compound.

Do retatrutide and semaglutide have the same side effects?

Both are dominated by dose-dependent gastrointestinal effects. Semaglutide has the more mature safety record; retatrutide trials additionally noted heart-rate increases and glucagon-arm parameters being characterised in Phase 3.

All figures are laboratory-preparation reference points, not dosing guidance. New-U Research Compounds supplies bacteriostatic water and research compounds strictly for laboratory research use only — not for human consumption .

Research-grade · >99% HPLC purity · COA per lot

Buy Retatrutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research